Cagrilintide combined with semaglutide (CagriSema) for treatment of type 2 diabetes In a recent small phase 2 trial (n=92), 3 groups of patients with type 2 diabetes were randomized to receive cagrilintide co-administered with semaglutide (the authors called this combination CagriSema), cagrilintide or semaglutide, both in doses escalated to 2.4 mg once weekly (table 1) [10]
Colon Rectal Surg
This ribosomal frameshifting event is stimulated by polyamines
General subcutaneous injection guidance usually points to the abdomen, outer thigh, and upper arm
Both studies were conducted in accordance with Good Clinical Practice, the Declaration of Helsinki and US Food and Drug Administration/European Medicines Agency guidelines for studies in people with renal or hepatic impairment [12,13,14,15]
The main use of injectable glutathione is skin whitening, which raises real ethical concerns rooted in colourism and racist beauty standards